Istradefylline – a first generation adenosine A2A antagonist for the treatment of Parkinson's disease

P Jenner, A Mori, SD Aradi… - Expert Review of …, 2021 - Taylor & Francis
Introduction It is now accepted that Parkinson's disease (PD) is not simply due to
dopaminergic dysfunction, and there is interest in developing non-dopaminergic …
被引用次数：67 相关文章

Istradefylline - a first generation adenosine A2A antagonist for the treatment of Parkinson's disease.

P Jenner, A Mori, SD Aradi… - Expert Review of …, 2021 - europepmc.org
Introduction It is now accepted that Parkinson's disease (PD) is not simply due to
dopaminergic dysfunction, and there is interest in developing non-dopaminergic …

[引用][C] Istradefylline – a first generation adenosine A2A antagonist for the treatment of Parkinson's disease

P Jenner, A Mori, SD Aradi, RA Hauser - Expert Review of …, 2021 - cir.nii.ac.jp
Istradefylline – a first generation adenosine A<sub>2A</sub> antagonist for the treatment of
Parkinson’s disease | CiNii Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ] 詳細 …

Istradefylline-a first generation adenosine A2A antagonist for the treatment of Parkinson's disease

P Jenner, A Mori, SD Aradi… - Expert review of …, 2021 - pubmed.ncbi.nlm.nih.gov
Introduction It is now accepted that Parkinson's disease (PD) is not simply due to
dopaminergic dysfunction, and there is interest in developing non-dopaminergic …

Istradefylline–a first generation adenosine A2A antagonist for the treatment of Parkinson's disease

P Jenner, A Mori, SD Aradi… - Expert Review of …, 2021 - kclpure.kcl.ac.uk
Introduction It is now accepted that Parkinson's disease (PD) is not simply due to
dopaminergic dysfunction, and there is interest in developing non-dopaminergic …